Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy

December 12, 2005

For years, we have heard about the health benefits of taking low doses of aspirin - preventing everything from Alzheimer's disease to heart attacks and stroke. The news about aspirin just keeps getting better. In a study published in the Dec. 9 issue of the Journal of Biological Chemistry, University of Pittsburgh researchers report that aspirin, combined with a promising new cancer therapy known as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), can induce cancer cells previously resistant to TRAIL therapy to self-destruct. The investigators say that if these findings hold up in larger studies, aspirin could become a routine therapy for helping to prevent the recurrence of many aggressive cancers, such as prostate and colon cancers.

"When cancers recur after initial therapy, they tend to be extremely aggressive and patient prognosis is poor," said Yong J. Lee, Ph.D., professor in the departments of surgery and pharmacology, University of Pittsburgh School of Medicine, and lead author of the study. "If we could find ways to prevent these secondary cancers from occurring, we could save many lives. Aspirin is a low-cost medicine that, in our studies, appears to have great potential for helping to prevent such cancer recurrences."

TRAIL is a protein that is expressed by cells of the immune system. Numerous studies have shown that TRAIL induces programmed cell death, or apoptosis, in cancer cells while having little or no effect in normal healthy cells. Apoptosis is one of several mechanisms by which damaged cells self-destruct and is the body's way of ensuring that only healthy cells reproduce. Most often, apoptosis eliminates rogue cells with damaged DNA or cells growing too quickly, but it also eliminates normal cells that have simply become obsolete as an organism grows and develops. Because cancer cells have lost their ability to undergo apoptosis, they continue to reproduce and spread their damaged progeny throughout the body.

In recent years, scientists have gained an increasingly sophisticated understanding of the mechanisms of apoptosis, which has led to the development of a number of therapies targeted to repairing or bypassing damaged apoptotic processes in cancer cells. TRAIL is one of the more promising of these agents, and a synthesized form of TRAIL has been shown in cell cultures and animal models to induce apoptosis alone and in combination with other drugs.

Unfortunately, studies have found that not all cancers are sensitive to TRAIL. In fact, many tumor cells are completely resistant to TRAIL's effects, creating an intensive search for compounds that can overcome this resistance. Based on other studies showing that aspirin can prevent the formation of tumors caused by ultraviolet radiation and carcinogens, Dr. Lee and his coworkers decided to test the ability of this compound to increase the sensitivity of TRAIL-resistant cancer cells to apoptosis. To do this, they treated human prostate cancer cells with aspirin and then treated the cells with a combination of TRAIL and/or aspirin. Cancer cells treated with either aspirin or TRAIL alone showed little or no cell death. However, pretreatment of the TRAIL-resistant cancer cells with aspirin promoted cell death when TRAIL was added.

To determine whether TRAIL was indeed inducing apoptosis in the aspirin-sensitized cells or killing the cells through some other mechanism, Dr. Lee and his coworkers looked for molecular signs of apoptosis. In the cancer cells pretreated with aspirin followed by TRAIL, there was significant cleavage, or cutting up, of a compound known as poly (ADP-ribose) polymerase, or PARP. PARP cleavage, a hallmark feature of apoptosis, did not occur in normal cells nor in cancer cells treated with aspirin alone.

Interestingly, the investigators discovered that, for PARP cleavage to occur, it was necessary to pretreat cancer cells with aspirin at least 12 hours before the administration of TRAIL. Dr. Lee and his colleagues also found that aspirin treatment causes cancer cells to decrease their production of a cellular protein known as Bcl-2, which has been shown in numerous studies to protect healthy cells from premature apoptosis. Decreased Bcl-2 production was the result of suppression of the Bcl-2 gene. Furthermore, when the investigators induced prostate and colon cancer cells to produce excess amounts of the Bcl-2 protein in the cells, the cells were still resistant to TRAIL-induced apoptosis even when they were pretreated with aspirin. According to Dr. Lee, this suggests that TRAIL induces apoptosis via cellular mitochondria.

"Bcl-2 inhibits the release of a compound known as cytochrome c from mitochondria, an organelle in the cell that regulates energy production as well as cell death. Therefore, we suspected that TRAIL might be inducing cell death through mitochondria-mediated apoptosis. In this study we demonstrated that aspirin can down-regulate Bcl-2 gene expression and consequently change the electrical potential of the mitochondrial membrane in cancer cells, thereby releasing cytochrome c and other apoptotic proteins."

Dr. Lee and his colleagues believe these findings could soon be applied in the clinical setting and result in the increased effectiveness of TRAIL for treating a number of aggressive cancers, particularly those that overexpress the human epidermal growth factor receptor 2 (HER-2/neu) gene. This gene is amplified up to 30 percent in some human cancers, which leads to an increase in the expression of the HER-2/neu protein on the cell surface. Numerous studies suggest that a high concentration of the HER-2/neu protein on the surface of cancer cells makes them more aggressive and difficult to treat. In this study, Dr. Lee and coworkers demonstrated that the combination of aspirin and TRAIL undercuts the effects of HER-2/neu overexpression.

"HER-2/neu overexpression in cancer cells, such as prostate and colon, is associated with a higher cell proliferation rate, faster metastases and greater tumor burden," explained Dr. Lee. "It is our hope that aspirin and other agents we are currently testing can negate this effect and dramatically improve the prognosis of patients with these types of cancer."

In addition to Dr. Lee, other contributors to this study include Kim M. Kim, Ph.D., and Jae J. Song, Ph.D., department of surgery, University of Pittsburgh School of Medicine, and Jee Young An, Ph.D., and Yong Tae Kwon, Ph.D., Center for Pharmacogenetics, department of pharmaceutical sciences, University of Pittsburgh School of Pharmacy.
-end-
This study was supported by grants from the National Cancer Institute, National Institutes of Health, the Elsa U. Pardee Foundation, The Pittsburgh Foundation, the Department of Defense Prostate Program Fund and Department of Defense Prostate Traineeship.

University of Pittsburgh Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.